Is Forest Labs' Nebivolol Ready for Prime Time?
602673
A Fool's prediction on the FDA's impending decision on approval.
510171
Questions linger about whether the companies can prove Vytorin fights heart attacks. At stake? Billions.
210111
Is it a wake-up call for the sleeping pill market? With Wednesday&#39;s approval of Sepracor&#39;s new drug, Lunesta, a taboo in the use of sleeping pills has been broken.
205700
Elan shares jumped this morning after it said that US regulators had approved it new once-a-month multiple sclerosis drug. Tysabri, developed by Elan and Biogen and formerly called Antegren, is the first kind
176403
NEW ORLEANS - The largest study ever done solely on Blacks with heart failure raises the controversial prospect of the first drug that might be marketed to a specific racial group.
573459
A key study of its lead drug proceeds faster than expected.
616424
NEW YORK  - Although it is well established   that the long-term use of beta-blocker drugs, such as Tenormin   and Lopressor, can improve survival and other outcomes after a   heart attack, most patients stop taking them after just a few   months, new research indicates.
459544
FRIDAY, Nov. 5 (HealthDayNews) -- Atenolol, a drug commonly prescribed to treat hypertension, doesn't prevent heart attacks or cardiovascular death any better than dummy drugs and is less effective than a wide variety of other blood pressure medications, a new study finds.
589141
TONIGHT A MEDICAL BREAKTHROUGH FOR AFRICAN-AMERICANS WITH HIGH BLOOD PRESSURE. SCIENTISTS SAY A NEW DRUG SHOWS PROMISE OF NEARLY DOUBLING A PERSON&#39;S CHANCES OF SURVIVING HEART FAILURE.
466493
Microsoft has tuned up its software for service providers, but consumers shouldn't expect much in the near future.Photos: Is IPTV software ready for prime time?IPTV chugs along
372356
NEW YORK, November 2  - Forest Laboratories Inc (FRX.NYS) witnessed a decline in its share price this morning, following the news of disappointing efficacy study results for the company&#39;s new hypertension drug.
220014
A breakthrough in physiological monitoring is about to take center stage  as Empirical Technologies prepares "BPGuardian&#8482;"  for commercial deployment.
325918
At least that&#39;s what NABI Biopharmaceuticals (Nasdaq: NABI) suggests based on the results of a small phase 2 trial with the drug NicVAX that was released yesterday.
436386
One of Forest Labs' Alzheimer's drugs fails in Phase III trials.
738863
Will broad, long beta tests mean fast adoption? Others are doubtful.
519863
The company faces a pivotal clinical trial.
166243
NEW YORK  - In people with diabetes and  heart failure, treatment with the beta-blocker metoprolol CR/XL  (controlled release/extended release) safely reduces the risk  of hospitalization and death, research shows.